The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)
-
Upload
noel-puckett -
Category
Documents
-
view
13 -
download
0
description
Transcript of The Role of Stakeholders in the Diabetes Multi-Center Research Consortium (DMCRC)
1
The Role of Stakeholders in the Diabetes Multi-Center
Research Consortium (DMCRC)
Joe V Selby MD, Director DMCRC Coordinating Center
Kaiser Permanente Northern CA
2
Diabetes Multi-Center Research Consortium (DMCRC)
Coordinating Center HMO Research Network DEcIDE Center
PI Joe Selby, MD Co-PI Patrick O’Connor MD
Affiliate Center Johns Hopkins University DEcIDE Center
PI Jodi Segal, MD Co-PI Eric Bass, MD
AHRQ Project Officers Barbara Bartman, MD MPH Scott Smith, R.Ph., M.S.P.H., Ph.D.
3
DMCRC – 1 Expanded Executive Committee
Also includes: Vanderbilt DEcIDE Center – Marie Griffin
MD, PI – Comparative Effectiveness of Oral Agents in Type 2 Diabetes
RTI DEcIDE Center – Suzanne West Ph.D. PI – Comparative Effectiveness of Oral Hypoglycemics on Chronic Kidney Disease and on Time to Initiation of Maintenance Insulin
4
Formation and Composition of DMCRC Stakeholders’ Committee
Formation: June 2009
Composition: – Expanded DMCRC Executive Committee– Government Agencies – AHRQ, NIDDK,
CMS, FDA, CDC, VA– Clinicians – ACP,AAFP, AADE– Patients - ADA, individual patient rep.
5
Purpose of the DMCRC Stakeholders’ Committee
To represent various constituencies and perspectives in a process of nominating and prioritizing topics for AHRQ-funded, empirical CER.
To review AHRQ-funded diabetes-related CER and provide input on:– Interpretation– Dissemination– Future Questions
6
Timeline of DMCRC Stakeholders’ Meetings
First Face-to-FaceMeetingJune 16, 2009
Initial Topic NominationsAnd PrioritizationFocus on Treatment
2009 2010
First Tele-ConferenceFeb 17, 2010
Focus on DM Prevention
Second Face-to-faceMeetingJuly 1, 2010
Review Ongoing CER ResearchTopic Re-prioritization forBoth treatment and Prevention
7
Format of DMCRC Stakeholders’ Meetings
Greetings and Update from AHRQ ~ 30 min
Presentation/Discussion of Research ~ 3 hrs – Findings from CER Work of Consortium members
– Review of recent clinical trials findings/implications
Nominations for Topics ~ 2 hrs– All participants invited to offer nominations
– Time for Brief Presentations
Voting ~ 30 min– assessing preferences of Stakeholders vs. EC
Brief Review of Results and Next Steps ~ 30 min
8
Secrets of the SauceDMCRC Stakeholders’ Committee
√ Meticulous planning with facilitator
√ Clear goals and game plan
√ Leave plenty of time for discussion
√ Facilitator to keep group on track, pull quiet ones out, chair topic nomination segment
√ Acknowledge relevant work of stakeholders
√ Demonstrate consequences of prior decisions and prioritization – i.e., funded projects
9
Stakeholder Prioritized Listof CER Questions on Treatment
Compare 2nd line therapies for their long-term effects (e.g., CVD endpoints) – 19 votes
Compare system approaches to coordinated care vs. usual care – 15 votes
Evaluate strategies to remove barriers to self care (including cost barriers) – 15 votes
Compare various providers and sites for providing behavior change support – 12 votes
Compare strategies for supporting insulin initiation – 9 votes
Compare system-level strategies for supporting adherence to medications – 9 votes
10
Stakeholder Prioritized Listof CER Questions on Prevention
Compare strengthened linkages between primary care and community resources vs. enhancing primary care to address overweight, lifestyle change – 25 votes
What are effective strategies for counseling patients in the primary care setting for weight loss? (Including issues of coverage) – 21 votes
Compare various approaches to GDM prevention and/or prevention of T2 DM in women with GDM. – 10 votes
11
Keeping Stakeholders Engaged
Emphasizing the funding by AHRQ of projects that address previously prioritized topics
Presenting and discussing findings from studies they recommended be done
Incorporating their comments and responses into ongoing analyses or taking their suggestions and designing next generation protocols
Identify effective, affordable (“Chevrolet”) programs to support individual behavior change – 10 votes
12
Challenges
Addressing or managing Stakeholder priority topics not squarely in COE purview– Prevention– Systems-level approaches– Engaging with community
Staying on top and keeping Stakeholders on top of all the research that AHRQ is funding
Adding stakeholders from delivery systems, possibly from industry
13
DataCommittee
ClinicalCommittee
MethodsCommittee
StakeholderCommittee
Project Manger
Executive Committee – Includes AHRQ, Coordinating, Affiliate Center Leadership
Next Steps
14
Next Steps
DataCommittee
ClinicalCommittee
MethodsCommittee
StakeholderCommittee
Project Manger
Executive Committee – Includes AHRQ, Coordinating, Affiliate Center Leadership